Skip to main content

FDA Alerts

The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.
The FDA has approved a new topical therapy for the treatment of actinic keratosis on the face or scalp.
The FDA recently approved a new topical treatment that is the first therapy approved in 40 years to target a new mechanism of action for acne.
The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
Back to Top